- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07800676
A+HA Premium Oral Hyaluronic Acid Drink Functional Evaluation Trial for Delaying Joint Pain
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Arthritis is an inflammation of one or more joints that is characterized by pain, stiffness (especially in the early morning or after exercise), swelling, deformation, and/or reduced mobility. Osteoarthritis, also known as degenerative arthritis, is caused by abnormal damage to the cartilage at the ends of bones. Some patients are caused by injury or congenital abnormalities in the proteins that make up cartilage.
Once the cartilage tissue changes from smooth to rough, or into small pieces. Cartilage is gradually destroyed, and the normally smooth surface becomes irregular. Osteoarthritis usually occurs in joints that require weight load, such as the spine, knees, hips and back, and is usually preceded by some pain and Symptoms of stiffness (mostly stiffness first, then pain), but swelling is not necessarily present. However, a small number of them will cause disability, but once the bones become more fragmented, they are more likely to cause fractures. When osteoarthritis is more severe, the bones can overgrow into osteophytes, known as bone spurs. When bone spurs develop, they can be detected with X-rays, usually in the neck or waist near degenerative cartilage. Formation, these phenomena will not produce any changes in appearance.
Osteoarthritis usually does not occur in adults under the age of 40. Most patients are over the age of 60. Symptoms may be so mild that you are unaware of them until detected by X-ray. The incidence is almost higher in women than in men. three times. Degenerative arthritis is increasing among the elderly in Taiwan. It has become a very important health problem and directly affects the quality of life. Pain control can improve the quality of life.
Previous studies have shown that orally administered hyaluronic acid (HA) can bind to toll-like receptor 4 (TLR-4) on intestinal epithelial cells, thereby increasing the secretion of the anti-inflammatory cytokine IL-10 and suppressor of cytokine signaling 3 (SOCS3), while suppressing the expression of the pro-inflammatory cytokine pleiotrophin, ultimately alleviating osteoarthritis. Regarding the regulation of cartilage degradation-related factors, HA can reduce irregularities on the cartilage surface as well as the loss of cartilage tissue and chondrocytes by suppressing the mRNA expression of MMP-3, MMP-9, and MMP-13 in cartilage tissue. In terms of oxidative stress, HA may also alleviate cartilage damage by downregulating inducible nitric oxide synthase (iNOS), thereby reducing nitric oxide (NO) production, and by inhibiting cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) production. To further enhance its efficacy in improving osteoarthritis, hyaluronic acid was combined with glucosamine and chondroitin. Previous studies have demonstrated that these two ingredients can improve connective tissue function and reduce cartilage matrix degradation. Therefore, the aim of this study was to investigate the effects of A+HA premium oral hyaluronic acid drink on improving knee pain.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Taipei, Taiwan
- Taipei Medical University
-
Contato:
- YiWen Chien, PhD
- Número de telefone: +886 2-27361661 #28363
- E-mail: ychien@tmu.edu.tw
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Aged 45 to 80 years.
- Knee osteoarthritis classified as Ahlbäck stage I or II, or Kellgren-Lawrence grade <3.
- A Visual Analogue Scale (VAS) pain score ≤3.
- A Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score >2 or a total WOMAC score >12.
Exclusion Criteria:
- Pregnant or breastfeeding women.
- Individuals with a history of knee joint trauma or surgery.
- A body mass index (BMI) ≥ 40 kg/m².
- Individuals with a psychiatric disorder.
- Individuals with severe cardiovascular disease, severe cerebrovascular disease, severe rheumatic disease, crystal deposition arthropathy, or cancer.
- Individuals who use a wheelchair and have a Manual Muscle Testing (MMT) grade ≤3 in the lower extremities, or who require a wheelchair due to physical discomfort.
- Use of anti-inflammatory analgesics, corticosteroids, or other medications that may affect the study outcomes within one week before the trial.
- Receipt of intra-articular corticosteroid injections, hyaluronic acid injections, platelet-rich plasma (PRP) therapy, or nerve block treatment within one month before the trial.
- Use of medications or consumption of foods that, in the judgment of a physician or dietitian, may affect the outcome measures.
- Any other condition considered by the physician to make the individual unsuitable for participation in the trial.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Placebo
Placebo use contents without active ingredients
|
1 drink daily
|
|
Experimental: A+HA premium oral hyaluronic acid drink
A+HA premium oral hyaluronic acid drink contains hyaluronic acid, glucosamine hydrochloride, and chondroitin
|
1 drink daily
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Points change of pain evaluation scale
Prazo: From the start to the end of treatment at 12 weeks
|
Self-assess pain using a visual analog scale (VAS), which is a straight line 10 cm in length, with 0 cm on the left representing no pain and 10 cm on the right representing extreme pain.
Explain to the subjects that the pain intensity increases from left to right.
Ask the subjects to mark the point on the line that corresponds to their pain level, and then record the distance in centimeters from the 0 cm mark.
Record the points that the subjects wrote.
|
From the start to the end of treatment at 12 weeks
|
|
Points change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Prazo: From the start to the end of treatment at 12 weeks
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), a widely used questionnaires used by health professionals to evaluate the condition of patients with osteoarthritis of the knee and hip, and the total score was 96 points (Minimum: 0 points; Maximum: 96 points).
The question content was divided into three parts: Pain (20 points), Stiffness (8 points), and Physical function (68 points).
The higher score meant worse knee joint function.
Record the points that the subjects got.
|
From the start to the end of treatment at 12 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Concentration change of aspartate aminotransferase (AST)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of alanine aminotransferase (ALT)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood glucose
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of high-density lipoprotein
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of low-density lipoprotein
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of free fatty acid
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of cholesterol
Prazo: From the start to the end of the treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of the treatment at 12 weeks
|
|
Concentration change of triglyceride
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Count change of differential count (DC)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Mean corpuscular volume (MCV)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hemoglobin
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of hematocrit
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Red blood cell count
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of gamma-glutamyl transferase (γ-GT)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of albumin
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of blood urea nitrogen (BUN)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of creatinine
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urea acid
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroid-stimulating hormone (TSH)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of triiodothyronine (T3)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of thyroxine (T4)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of sodium (Na)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of potassium (K)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of calcium (Ca)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of magnesium (Mg)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of phosphorus (P)
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Change of urine pH value
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine protein
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
|
Concentration change of urine glucose
Prazo: From the start to the end of treatment at 12 weeks
|
Measured from participants' blood samples for safety monitoring purposes
|
From the start to the end of treatment at 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- N202606002
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .